Vistagen Investors Face March 16 Lead‑Plaintiff Deadline as Law Firms Seek Clients

Plaintiffs say upbeat statements about fasedienol misled investors after the drug’s Phase 3 failure.

Overview

A federal securities class action has been filed against Vistagen tied to statements about fasedienol and the PALISADE‑3 trial.
Investor notices from Faruqi & Faruqi, Rosen Law Firm, and the Schall Law Firm urge VTGN shareholders to consider seeking lead‑plaintiff status by March 16, 2026.
The putative class period spans April 1, 2024 through December 16, 2025, according to the firms’ announcements.
On December 17, 2025, Vistagen reported PALISADE‑3 failed its primary SUDS endpoint, and the stock opened down more than 81% at $0.88.
No class has been certified, investors are not represented unless they retain counsel, and serving as lead plaintiff is not required to share in any potential recovery.